Study data confirm the results of the performance of the Aurora test. The pilot study already showed a positive outcome and has now been confirmed in a large patient cohort. The latest study included a total of 633 patients. 113 patients were tested using the Aurora test. The other 520 patients served as a control group.
The Aurora test results in non-invasive oocyte quality scoring. The test is based on cumulus cell analysis combined with morphology scoring. The study data have confirmed the results of the pilot study. It has concluded the Aurora test can increase the clinical pregnancy and live birth rates in Day 3 eSET ICSI patients. To learn more about the Aurora test for ICSI, click here.
The paper reports positive results of a prospective study on 633 patients (113 tested with the Aurora Test and 520 control patients). The study data confirm the results of the performance of the Aurora Test nicely.
- The clinical pregnancy rate (CPR) was 61% in the experimental arm (n = 113) compared to 29% in the control arm (n = 520, p < 0.0001).
- Furthermore, the live birth rate (LBR) in the experimental arm (50%) was significantly higher than in the control arm (27%,p < 0.0001).
- The time-to-pregnancy was significantly shortened by 3 transfer cycles independent of the number of embryos available on Day 3 (Kaplan-Meier, p < 0.0001).
Read the full publication in BioMedicCentral here:
Van Vaerenbergh I, et al, Improved clinical outcomes after non-invasive oocyte selection and Day 3 eSET in ICSI patients. Reprod Biol Endocrinol. 2021 Feb 19;19(1):26.